Summary of results for people diagnosed with Non-Hodgkin Lymphoma (NHL) in England (2022) and Wales (2023).





Diagnosis and staging

Diagnoses per year

England

15,433 diagnosed in 2022

729 diagnosed in 2023

Grade of lymphoma

England 2022 high-grade 50 %, low-grade 49%, not classified 0.8%

Wales 2023 high-grade 50%, low-grade 45%, not classified 5%

33%



MDT discussion within 4 weeks of diagnosis, where recorded

England 2022 - 60.0%, (highgrade 65%, low-grade 54%)

No data on MDT discussion was provided for Wales



Mean age at diagnosis for both England & Wales

Emergency presentation

England 2022 - 28%

Development work underway for Welsh data






Clinical Nurse Specialist (CNS) seen, where recorded

England 2022 83% Wales 2023 96%

40% data completeness for England 2022

Treatment



Timing of Radiotherapy delivery

Percentage of people diagnosed with high-grade lymphoma, who received radiotherapy within 8 weeks of end of first line SACT.



End date for 1st line chemotherapy was not provided for Wales so this indicator could not be measured.

Trial Participation 2%

Percentage of people with NHL who are recorded as having received an episode of care that was delivered as part of a clinical trial in England 2022*

* Note 47% data missing. No data on trial participation for Wales was available

91%

Fngland 2022


Survival

One-year survival outcomes



Two-year survival outcomes*

Not available for Wales due to insufficient follow up period



Overall



63%

England 2022



low-grade



94%

Wales 2023

high-grade